Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is frequently resistant to chemotherapy. However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in HCC and overcomes chemotherapy resistance in other settings. We studied the efficacy of combining the anti-EGFR antibody cetuxi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sanoff, Hanna K., Bernard, Stephen, Goldberg, Richard M., Morse, Michael A., Garcia, Reynaldo, Woods, Lynna, Moore, Dominic T., O'Neil, Bert H.
Format: Artigo
Idioma:Inglês
Publicat: International Society of Gastrointestinal Oncology 2011
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3201640/
https://ncbi.nlm.nih.gov/pubmed/22043322
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars